The GLP-1 story took a turn this spring. On 1 April 2026, the FDA approved orforglipron (brand name Foundayo, Eli Lilly), the first oral small-molecule, non-peptide GLP-1 receptor agonist for weight management. For a drug class that has been defined by injectable peptides, and more recently by a fasting-dependent peptide pill, a small molecule that works as a daily tablet with no food or water rules is a real shift. It has also revived an old question for our field: if small molecules can do this, where does it leave peptides?
What changed
The contrast is the point. Oral semaglutide, a peptide, needs the absorption enhancer SNAC and strict fasting, because only about one percent of an oral peptide dose is absorbed. Orforglipron is a small molecule, so it skips the enhancer, can be taken at any time, and, as trial investigators have noted, is easier and cheaper to manufacture than a GLP-1 peptide. Phase 3 data presented at the ADA meeting in June 2026 showed it holding its own against oral semaglutide on efficacy, with a somewhat different tolerability profile. On paper, that is a competitive, lower-cost oral option in the biggest drug market of the decade.
Our take
It would be easy to read this as the beginning of the end for therapeutic peptides. We think that is the wrong lesson.
Orforglipron works because GLP-1 turned out to be one of the rare targets a small molecule can hit well. Most of the targets peptides are built for, including protein-protein interactions and large, shallow binding sites, are exactly the ones small molecules struggle with. That is the reason the peptide modality exists, and one successful small molecule does not change the underlying biology.
It also helps to look at the rest of the GLP-1 field. The class is still overwhelmingly peptide: semaglutide, tirzepatide, and the next wave of multi-target agonists in development are peptides or peptide-based, and the market around them is still growing fast. More approved and investigational products, not fewer, means more demand for peptide APIs, reference standards, and research peptides. The oral-peptide absorption problem that orforglipron sidesteps is itself pulling investment into peptide delivery and peptide modification, from absorption enhancers to lipidation, which is work the peptide sector is well placed to do.
The practical read for biotech and pharma teams is to treat modality as a property of the target, not a trend. Small molecules, peptides, and biologics each win where their chemistry fits, and the peptide pipeline, with well over two hundred candidates in clinical development across many targets, is far too broad to be defined by a single metabolic approval. For our part, we see steady demand across the board, from custom peptide synthesis and peptide modification through to large-scale peptide synthesis.
Working on a peptide program, or weighing a modality decision? Reach our team at peptide@synpeptide.com.
-
Synpeptide
peptide-focused CRO/CDMO company
The SynPeptide Research Team brings together scientists specializing in peptide synthesis, purification, and analytical characterization. Drawing on hands-on laboratory experience across custom and catalog peptides, the team shares evidence-based insights for researchers, formulators, and product developers. All content is reviewed against current scientific literature and internal quality-control data, reflecting SynPeptide's commitment to accuracy, reproducibility, and the responsible communication of peptide science.
